06.09.2011

NNE Pharmaplan Extends International Business with A New Structure

Leading The Way - With sales of around €200 million in 2010, NNE Pharmaplan is one of the world's leading engineering and consulting companies for the pharmaceutical and biotechnology industries. Last year the group, whose headquarters are in Copenhagen, changed its organizational structure in order to improve its service to international customers and more consistently exploit opportunities for growth.

The subsidiaries in Germany, Switzerland and France are part of the Central Europe Region. The German headquarters is in Bad Homburg, near Frankfurt. Dr. more14.06.2011

E&Y Sees $1-5 Billion As Sweet Spot For Biotech M&A

Biotech deals in the $1 billion to $5 billion range are likely to be a sweet spot for drug companies looking to bolster their pipelines through M&A in an increasingly tough environment, Ernst & Young said.        more07.06.2011

Actelion Shakes Up Board, Appoints COO

Actelion, Europe's largest biotech company which has been under pressure from activist investor Elliott Advisors, is changing its management structure, including appointing a chief operating officer. Actelion said in a statement it had appointed Otto Schwarz, head of business strategy and operations at Actelion since 2008, as COO, allowing Chief Executive Jean-Paul Clozel to focus more on strategic matters. more04.05.2011

Some Key Facts On The Actelion Vs. Asahi Case

Europe's largest biotech Actelion was dealt a blow when a jury in a Californian court said Japanese drugmaker Asahi Kasei should be awarded up to $547 million in a licensing dispute. The decision comes at a difficult time for Actelion, which is also under fire from largest shareholder Elliott Advisors and will have to square up to the New York-based hedge fund at its annual general meeting in Basel on Thursday. Here are some key facts about the Actelion vs. Asahi case. more02.05.2011

Pressure On Actelion Rises After Asahi Case Decision

Swiss biotech group Actelion is now facing a tougher battle at its annual general meeting this week after a jury decided Asahi Kasei Pharma Corporation should be awarded up to $547 million. Actelion said it may appeal the jury's decision in the Superior Court of the State of California, which regards a licensing and development dispute with Actelion's unit CoTherix. more02.05.2011

Asahi Awarded Up To $547 Million In Actelion Case

Swiss biotech group Actelion may appeal against a jury's decision in a Californian court to award Asahi Kasei Pharma Corporation up to $547 million in a dispute with Actelion unit CoTherix. Actelion said in a statement that the Superior Court of the State of California jury would on Tuesday continue deliberations regarding punitive awards. more11.04.2011

Sanofi Completes Genzyme Takeover

Sanofi-Aventis said it has completed its takeover of U.S. biotechnology company Genzyme. The companies agreed in February on a deal worth about $20.1 billion. The acquisition gives Sanofi access to Genzyme's business in treating rare diseases and is expected to help the company combat sales erosion from drugs facing cheap generic competition. more04.04.2011

Sanofi Says Gains Control Of Genzyme

French drugmaker Sanofi-Aventis completed its improved $20.1 billion offer for Genzyme allowing it to begin merging the U.S. biotech into its business and add rare diseases to its growth areas. more17.02.2011

French Drugmaker Sanofi-Aventis SA Reaches Finall Agreement to Buy Genzyme Corp

French drugmaker Sanofi-Aventis SA agreed to buy Genzyme Corp with a sweetened $20.1 billion cash offer, plus payments tied to the success of the U.S. biotech group's drugs, the companies said on Wednesday. more16.02.2011

Sanofi-Aventis SA has agreed in principle to acquire Genzyme Corp for $19.2 billion in cash

Sanofi-Aventis SA has agreed in principle to acquire Genzyme Corp for $19.2 billion in cash plus future payments based on the performance of an experimental Genzyme drug, according to two sources with knowledge of the talks. Under the agreement, Genzyme investors will receive $74 per share in cash plus a contingent value right, or CVR, tied to Genzyme's experimental multiple sclerosis drug Lemtrada. The value of the CVR could not immediately be established.
more